Literature DB >> 25740143

Collagen I-induced dendritic cells activation is regulated by TNF-alpha production through down-regulation of IRF4.

Barun Poudel1, Hyeon-Hui Ki, Young-Mi Lee, Dae-Ki Kim.   

Abstract

Previously we have shown that collagen I enhances the maturation and function of dendritic cells (DCs). Inflammatory mediators such as tumour necrosis factor (TNF)- alpha, interleukin (IL)-1 beta and lipopolysaccharide (LPS) are also known to activate DCs. Here we investigated the involvement of TNF-alpha on the collagen I-induced DCs activation. TNF-a neutralization inhibited collagen I-induced IL-12 secretions by DCs. Additionally, we observed suppression of collagen I-induced costimulatory molecules expression along with down-regulation of genes involved in DCs activation pathway. Furthermore, TNF- alpha inhibition upon collagen Istimulation up-regulated the expression of interferon regulatory transcription factor IRF4, when compared to collagen I only treated cells. Collectively, our data demonstrate that collagen I induce TNF- alpha production, which is crucial for the activation and function of DCs, through down-regulation of IRF4, and implicates the importance in development of anti- TNF-alpha therapeutics for several inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25740143     DOI: 10.1007/s12038-015-9507-7

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  29 in total

Review 1.  Tolerogenic dendritic cells.

Authors:  Ralph M Steinman; Daniel Hawiger; Michel C Nussenzweig
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

2.  Discoidin domain receptor 2 is involved in the activation of bone marrow-derived dendritic cells caused by type I collagen.

Authors:  Ji-Eun Lee; Chon-Sik Kang; Xiu-Ying Guan; Beom-Tae Kim; Sang-Hyun Kim; Young-Mi Lee; Woo-Sung Moon; Dae-Ki Kim
Journal:  Biochem Biophys Res Commun       Date:  2006-11-13       Impact factor: 3.575

Review 3.  Treatment of rheumatoid arthritis: state of the art 2009.

Authors:  Ronald F van Vollenhoven
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

4.  Differential expression and distinct functions of IFN regulatory factor 4 and IFN consensus sequence binding protein in macrophages.

Authors:  S Marecki; M L Atchison; M J Fenton
Journal:  J Immunol       Date:  1999-09-01       Impact factor: 5.422

5.  CCR7 essentially contributes to the homing of plasmacytoid dendritic cells to lymph nodes under steady-state as well as inflammatory conditions.

Authors:  Sebastian Seth; Linda Oberdörfer; Rebecca Hyde; Kirstin Hoff; Verena Thies; Tim Worbs; Susanne Schmitz; Reinhold Förster
Journal:  J Immunol       Date:  2011-02-04       Impact factor: 5.422

6.  Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures.

Authors:  C Winzler; P Rovere; M Rescigno; F Granucci; G Penna; L Adorini; V S Zimmermann; J Davoust; P Ricciardi-Castagnoli
Journal:  J Exp Med       Date:  1997-01-20       Impact factor: 14.307

7.  Neutralization of tumor necrosis factor activity shortly after the onset of dendritic cell hematopoiesis reveals a novel mechanism for the selective expansion of the CD14-dependent dendritic cell pathway.

Authors:  F Santiago-Schwarz; M McCarthy; J Tucci; S E Carsons
Journal:  Blood       Date:  1998-08-01       Impact factor: 22.113

8.  Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells.

Authors:  R Thomas; L S Davis; P E Lipsky
Journal:  J Immunol       Date:  1994-03-01       Impact factor: 5.422

9.  IFN regulatory factors 4 and 8 expression in the NOD mouse.

Authors:  Gilles Besin; Simon Gaudreau; Emilie Dumont-Blanchette; Michael Ménard; Chantal Guindi; Gilles Dupuis; Abdelaziz Amrani
Journal:  Clin Dev Immunol       Date:  2011-05-15

10.  Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1.

Authors:  J A Roake; A S Rao; P J Morris; C P Larsen; D F Hankins; J M Austyn
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.